News

GlobalData on MSN3d
GSK and iTeos drop anti-TIGIT drug following trial failure
GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a ...
iTeos Therapeutics: TIGIT Falls, And A Zombie Rises?
Teos Therapeutics faces significant setbacks with the discontinuation of their TIGIT program and belrestotug, leaving them ...
iTeos, GSK to shelve TIGIT drug after study setback
The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...
BioSpace3d
GSK, iTeos Abandon TIGIT Therapy, Adding to Long List of Recent Class Failures
Belrestotug showed underwhelming efficacy outcomes in mid-stage studies of non-small cell lung cancer and head and neck ...
Fierce Biotech4d
GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs
GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...
The American Journal of Managed Care4d
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising ...
Applied Clinical Trials Online3d
iTeos and GSK Halt TIGIT Antibody Belrestotug Development After Phase II Trials Miss Efficacy Marks in NSCLC and HNSCC
Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...
pharmaphorum3d
GSK pays $1.2bn for liver drug as it culls TIGIT programme
GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...
BioWorld4d
More TIGIT trouble: GSK and Iteos part ways
TIGITs took another tumble with GSK plc’s decision to end a development program and a collaboration with Iteos Therapeutics Inc. New top-line results from a phase II study in non-small-cell lung ...